Skip to main content
. 2020 Apr 11;4(5):880–888. doi: 10.1002/jgh3.12339

Figure 3.

Figure 3

Treatment response to lenvatinib based on baseline ANG2 and FGF19 levels. In patients with low baseline FGF19 and ANG2 levels, the objective response rate (ORR) was 100% (9/9). Conversely, in those with high levels of both markers, the ORR to lenvatinib was 13% (1/8).